Explainer
Medicare coverage of GLP-1 obesity drugs explained
CMS says Medicare and Medicaid generally do not cover GLP-1 drugs when they are used for weight loss.[1] Since 1 July 2026, a temporary CMS demonstration called the Medicare GLP-1 Bridge has given eligible Part D enrollees certain GLP-1 drugs for $50 a month. It runs through 31 December 2027.[2][3] CMS's BALANCE Model, announced in December 2025, was due to reach Part D in January 2027, but CMS now says it will not launch in Medicare in 2027.[4][5]
This page explains coverage rules and prices set by CMS. It is general information, not medical or financial advice, and it gives no guidance on doses. Whether a GLP-1 drug is right for you is a question for your clinician, and your plan or Medicare can answer coverage questions.
How the drugs work is covered in how GLP-1 drugs work. This page covers who pays for them in Medicare and Medicaid.
The starting point
CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight-loss indication.[1] On 6 November 2025 the White House announced a pricing agreement with Eli Lilly and Novo Nordisk. It set Medicare prices for Ozempic, Wegovy, Mounjaro and Zepbound at $245 a month, with a $50 monthly copay for beneficiaries.[6] The White House said this would let Medicare cover Wegovy and Zepbound for patients with obesity and related conditions for the first time.[7]
The Medicare GLP-1 Bridge (July 2026 to December 2027)
The Medicare GLP-1 Bridge is a time-limited CMS demonstration. It gives eligible Part D enrollees certain GLP-1 drugs for $50 a month from 1 July 2026 through 31 December 2027.[2] Novo Nordisk reported that it began on 1 July 2026 and covers a majority of Medicare beneficiaries, and Lilly reported coverage of Zepbound and Foundayo under it.[3]
The Bridge sits outside the normal Part D benefit, so Part D plans carry no risk for these drugs. The $50 copay does not count toward the Part D deductible or the annual out-of-pocket total, and the low-income subsidy does not apply.[8]
The BALANCE Model
On 23 December 2025 CMS announced the voluntary BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. Under it, CMS negotiates prices and coverage terms with GLP-1 manufacturers on behalf of state Medicaid agencies and Part D plans. It was to launch in Medicaid as early as May 2026 and in Part D in January 2027.[4]
- Medicare. CMS now says BALANCE will not launch in Medicare in 2027. The Bridge runs through 31 December 2027 instead, while CMS collects use data to share with Part D plans before a potential launch.[5]
- Medicaid. States can join from May 2026 through 1 January 2027. Coverage depends on which states and manufacturers take part, patients must meet negotiated criteria including prior authorisation, and CMS says the model does not guarantee coverage for any individual.[9]
- Drugs. CMS lists all formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo.[10] To qualify, a drug must act on GLP-1, GIP or glucagon receptors and have trial evidence of at least 9.5% average weight loss at an FDA-approved dose.[11]
Negotiated prices from 2027
Separately, under the Medicare Drug Price Negotiation Program, CMS set a negotiated 30-day price of $274 for Ozempic, Rybelsus and Wegovy, against a 2024 list price of $959. The price takes effect on 1 January 2027.[12] See Medicare drug price negotiation and the GLP-1 access and pricing debate.
Key dates
- 6 November 2025: The White House announces the Lilly and Novo Nordisk pricing agreement.[6]
- 23 December 2025: CMS announces the BALANCE Model.[4]
- May 2026: State Medicaid agencies can begin joining BALANCE.[9]
- 1 July 2026: The Medicare GLP-1 Bridge begins.[3]
- 1 January 2027: Negotiated Medicare prices for semaglutide drugs take effect.[12]
- 31 December 2027: The Bridge is scheduled to end.[5]
Read next
Medicare Drug Price Negotiation Program
How Medicare negotiates drug prices: the 10 drugs priced from 2026, 15 from 2027 including Ozempic, the 2028 list with first Part B drugs, and what is next.
Questions readers ask
Does Medicare cover Wegovy or Zepbound for weight loss?
Not through the normal Part D benefit. CMS says Medicare generally does not cover GLP-1 drugs for weight loss. From 1 July 2026 to 31 December 2027, eligible Part D enrollees can get certain GLP-1 drugs for $50 a month through the Medicare GLP-1 Bridge demonstration.[1][2]
What is the Medicare GLP-1 Bridge?
A time-limited CMS demonstration that runs outside the normal Part D benefit, so Part D plans carry no risk for the drugs. The $50 copay does not count toward the Part D deductible or out-of-pocket total, and the low-income subsidy does not apply to it.[2][8]
What is the BALANCE Model?
A voluntary CMS Innovation Center model announced on 23 December 2025. CMS negotiates GLP-1 prices and coverage terms with manufacturers on behalf of state Medicaid agencies and Part D plans. It could start in Medicaid as early as May 2026.[4]
Will BALANCE start in Medicare in 2027?
No. CMS says BALANCE will not launch in Medicare in 2027. The Bridge runs through 31 December 2027 instead, while CMS gathers data ahead of a potential Part D launch.[5]
Which drugs are included?
CMS lists all formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo for the BALANCE Model.[10]
Does Medicaid now cover GLP-1s for weight loss?
CMS says Medicaid generally does not cover GLP-1 drugs for weight loss. BALANCE gives state Medicaid agencies a way to cover them on negotiated terms, but coverage depends on which states and manufacturers take part, patients must meet criteria including prior authorisation, and CMS says the model does not guarantee coverage for any individual.[1][4][9]
Sources
· 12 claims from 6 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
CMS says Medicare and Medicaid generally do not cover GLP-1 drugs when they are used for weight loss. confirmedas of 2026-11-14
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model · Centers for Medicare & Medicaid Services (CMS Innovation Center) · Primary source · Key Points, Problem (retrieved 2026-11-14)
- [2]
CMS's Medicare GLP-1 Bridge, a time-limited demonstration, gives eligible Part D enrollees certain GLP-1 medicines for $50 a month from 1 July 2026 through 31 December 2027. confirmedas of 2026-05-06
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries · Centers for Medicare & Medicaid Services · Primary source · 2026-05-06 · Press release (program dates and $50 monthly supply) (retrieved 2026-10-10)
- [3]
Novo Nordisk reported that the Bridge programme began on 1 July 2026 and covers a majority of Medicare beneficiaries, and Lilly reported Foundayo and Zepbound coverage under it. confirmedas of 2026-08-05
- Novo Nordisk Form 6-K, financial report for the period 1 January 2026 to 30 June 2026 · Novo Nordisk (SEC filing) · Primary source · 2026-08-04 (retrieved 2026-10-10)
- Eli Lilly and Company Form 8-K exhibit 99.1, second-quarter 2026 results · Eli Lilly and Company (SEC filing) · Primary source · 2026-08-05 (retrieved 2026-10-10)
- [4]
On 23 December 2025 CMS announced the voluntary BALANCE Model, under which it negotiates GLP-1 prices and coverage terms with manufacturers on behalf of state Medicaid agencies and Medicare Part D plans, to launch in Medicaid as early as May 2026 and in Part D in January 2027. confirmedas of 2025-12-23
- CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines, Promote Healthier Living · Centers for Medicare & Medicaid Services · Primary source · 2025-12-23 · Press release dated Dec 23, 2025 (retrieved 2026-11-14)
- CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines, Promote Healthier Living · Centers for Medicare & Medicaid Services · Primary source · 2025-12-23 (retrieved 2026-11-14)
- [5]
CMS later said the BALANCE Model would not launch in Medicare in 2027 and that the Medicare GLP-1 Bridge would run through 31 December 2027, letting CMS gather utilisation data ahead of a potential Part D launch. confirmedas of 2026-11-14
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model · Centers for Medicare & Medicaid Services (CMS Innovation Center) · Primary source · FAQs (retrieved 2026-11-14)
- Medicare GLP-1 Bridge · Centers for Medicare & Medicaid Services · Primary source · 2026-07-13 · FAQs (page last modified 07/13/2026) (retrieved 2026-11-14)
- [6]
Under a 6 November 2025 agreement announced by the White House with Eli Lilly and Novo Nordisk, Medicare prices for Ozempic, Wegovy, Mounjaro and Zepbound were set at $245 a month with a $50 monthly copay for beneficiaries, and Ozempic and Wegovy at $350 through the TrumpRx website. confirmedas of 2025-11-06
- Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-11-06 (retrieved 2026-10-10)
- Novo, Lilly cut deal with Trump to lower prices of obesity drugs · Healthcare Dive · Secondary source · 2025-11-06 (retrieved 2026-10-10)
- [7]
The White House said the November 2025 pricing agreement with Eli Lilly and Novo Nordisk would let Medicare cover Wegovy and Zepbound for patients with obesity and related conditions for the first time, with a $50 monthly copay. confirmedas of 2025-11-06
- Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-11-06 (retrieved 2026-10-10)
- Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-11-06 (retrieved 2026-10-10)
- [8]
The Bridge runs outside the normal Part D benefit, so Part D plans carry no risk for the drugs; the $50 copay does not count toward the Part D deductible or out-of-pocket total, and no low-income subsidy applies to it. confirmedas of 2026-07-13
- Medicare GLP-1 Bridge · Centers for Medicare & Medicaid Services · Primary source · 2026-07-13 · FAQs, What is the Medicare GLP-1 Bridge? (retrieved 2026-11-14)
- Medicare GLP-1 Bridge · Centers for Medicare & Medicaid Services · Primary source · 2026-07-13 · FAQs, copay (retrieved 2026-11-14)
- [9]
State Medicaid agencies can join BALANCE from May 2026 through 1 January 2027; Medicaid coverage depends on manufacturer and state participation, patients must meet negotiated criteria including prior authorisation, and CMS says the model does not guarantee coverage for any individual. confirmedas of 2026-11-14
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model · Centers for Medicare & Medicaid Services (CMS Innovation Center) · Primary source (retrieved 2026-11-14)
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model · Centers for Medicare & Medicaid Services (CMS Innovation Center) · Primary source (retrieved 2026-11-14)
- [10]
CMS lists the drugs in the BALANCE Model as all formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo. confirmedas of 2026-11-14
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model · Centers for Medicare & Medicaid Services (CMS Innovation Center) · Primary source · FAQs, What drugs are included in the BALANCE Model? (retrieved 2026-11-14)
- [11]
To be eligible for BALANCE, a drug must act on GLP-1, GIP or glucagon receptors and have trial evidence of at least 9.5% average weight reduction at an FDA-approved dose. confirmedas of 2026-11-14
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model · Centers for Medicare & Medicaid Services (CMS Innovation Center) · Primary source · Participant Information (also 'GIP receptor agonist, GLP‐1 receptor agonist, glucagon receptor agonist, or in any combination') (retrieved 2026-11-14)
- [12]
Under the Medicare Drug Price Negotiation Program, CMS set a negotiated 30-day price of $274 for Ozempic, Rybelsus and Wegovy, against a 2024 list price of $959, effective 1 January 2027. confirmedas of 2025-11-25
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) · Centers for Medicare & Medicaid Services · Primary source · 2025-11-25 · Q&A and price table (Ozempic; Rybelsus; Wegovy, list price $959) (retrieved 2026-10-10)
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) · Centers for Medicare & Medicaid Services · Primary source · 2025-11-25 · Price table, row "Ozempic; Rybelsus; Wegovy": negotiated 30-day price, 2024 list price, discount (PDF table; check by hand) (retrieved 2026-10-10)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: May 14, 2027.
Cite this page
"Medicare coverage of GLP-1 obesity drugs explained." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/medicare-glp-1-coverage
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.